Tag: Intellia Therapeutics
March 20, 2020
The Rise of CRISPR Technology
CRISPR technology is a rapidly growing component of the genetics industry. Here's what investors need to know about its future... February 27, 2020
Intellia Announces Q4 and Full-Year 2019 Financial Results
Intellia Therapeutics reported operational highlights and financial results for the fourth quarter and year ended December 31, 2019.
November 13, 2018
CRISPR Trials to Watch in 2018
CRISPR Cas-9 gene editing is finally in clinical studies. Here's an overview of CRISPR genetics testing trials currently in progress. August 24, 2018
Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution
Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, presented data from studies... March 14, 2018
Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR technology, announced financial results and...
March 8, 2018
4 Gene Editing Technologies Explained
We look at four types of gene editing currently in clinical trials, as well as the pros and cons of... February 27, 2018